Hangzhou Yuannang Biotechnology Co., Ltd.
PrivateLast Round
Series A
Sep 11, 2025
Total Funding Raised
$14M
Company Overview
Hangzhou Yuannang Biotechnology Co., Ltd. operates in Healthcare & Life Sciences and is based in Hangzhou. Its latest recorded funding round was a Series A round in September 2025.
Hangzhou Yuannang Biotechnology Co., Ltd. is a biotechnology company that develops biodegradable bone adhesives for orthopedic trauma repair.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Advanced Materials, Clinical Trials
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hangzhou Yuannang Biotechnology Co., Ltd. Comparables
Compare Hangzhou Yuannang Biotechnology Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| RevBio, Inc. | 85% | |
| Biomimetic Innovations | 80% | |
| Sanara Medtech Inc | 70% |
For institutional investors. Book with your work email.
Hangzhou Yuannang Biotechnology Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 11, 2025 | ||||
| Early Funding | Aug 1, 2022 | ||||
| Angel | Oct 1, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Hangzhou Yuannang Biotechnology Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Zheshang Venture Capital | Angel, Series A, Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 9, 2025
Monthly visitors grew 56% MoM, reaching 2.3 million.
- Sep 11, 2025
$14M round led by Zheshang Venture Capital.
For institutional investors. Book with your work email.
Hangzhou Yuannang Biotechnology Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Hangzhou Yuannang Biotechnology Co., Ltd.'s valuation, stock price, and market status.
Is Hangzhou Yuannang Biotechnology Co., Ltd. a public or private company?
Hangzhou Yuannang Biotechnology Co., Ltd. is a private company.
What is the current stock price of Hangzhou Yuannang Biotechnology Co., Ltd.?
Hangzhou Yuannang Biotechnology Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Hangzhou Yuannang Biotechnology Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Hangzhou Yuannang Biotechnology Co., Ltd. worth (valuation)?
Valuation information for Hangzhou Yuannang Biotechnology Co., Ltd. is not publicly available.
Can I buy Hangzhou Yuannang Biotechnology Co., Ltd. stock?
Hangzhou Yuannang Biotechnology Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Hangzhou Yuannang Biotechnology Co., Ltd.'s last funding round?
Hangzhou Yuannang Biotechnology Co., Ltd.'s most recent funding round was Series A on September 11, 2025.
Who are the main investors in Hangzhou Yuannang Biotechnology Co., Ltd.?
Key investors in Hangzhou Yuannang Biotechnology Co., Ltd. include Zheshang Venture Capital.
Will Hangzhou Yuannang Biotechnology Co., Ltd. IPO soon?
No public IPO plans have been announced for Hangzhou Yuannang Biotechnology Co., Ltd..
How can I track Hangzhou Yuannang Biotechnology Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Hangzhou Yuannang Biotechnology Co., Ltd.'s shares on secondary markets.